FAM171A1

Across TCGA pan-cancer cohorts, FAM171A1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FAM171A1 data layer compared with 21 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lymphoid neoplasm diffuse large b-cell lymphoma (DLBC), where higher FAM171A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FAM171A1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and BLCA show a favorable association.

DLBC, UCEC, and LUSC are the cancer types where FAM171A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
DLBC	OS	Median	All	0.049	0.765	<.001	30	view →
UCEC	OS	Median	II,III,IV	0.937	0.454	.014	26	view →
LUSC	DFS	Median	II,III,IV	0.079	0.750	<.001	21	view →
UVM	DFS	Median	All	0.079	0.746	<.001	18	view →
BLCA	DFS	Median	III,IV	1.000	0.268	.016	17	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FAM171A1–DLBC (OS)

Open the DLBC breakdown →